Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FLUSALEM: SC Alemtuzumab and Oral Fludarabine in R/R CLL
NCT00565981Phase 2Completed
- Sponsor
- Arbeitsgemeinschaft medikamentoese Tumortherapie
- Start
- Mar 2004
- Primary completion
- Feb 2008
- Modality
- Monoclonal Antibodies, Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
A Phase 2 trial of alemtuzumab, fludarabine in chronic lymphocytic leukemia (CLL), sponsored by Arbeitsgemeinschaft medikamentoese Tumortherapie. Started Mar 2004; status: completed.
02
Drugs
alemtuzumabfludarabine
03
Conditions
chronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT00565981.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00565981.